HC Wainwright set a $9.00 price target on AVEO Pharmaceuticals (NASDAQ:AVEO) in a report published on Tuesday, The Fly reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on AVEO. BidaskClub upgraded shares of AVEO Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Tuesday, September 11th. Zacks Investment Research lowered shares of AVEO Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, October 23rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. AVEO Pharmaceuticals currently has a consensus rating of Buy and an average price target of $6.33.

AVEO Pharmaceuticals stock traded down $0.14 during mid-day trading on Tuesday, hitting $1.86. The company had a trading volume of 4,898,923 shares, compared to its average volume of 3,896,796. The firm has a market capitalization of $239.25 million, a P/E ratio of -11.63 and a beta of 2.00. AVEO Pharmaceuticals has a 1 year low of $1.78 and a 1 year high of $3.59.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.09). The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $1.35 million. As a group, sell-side analysts predict that AVEO Pharmaceuticals will post -0.25 earnings per share for the current year.

In other AVEO Pharmaceuticals news, major shareholder Equity Opportunities Iv Growth bought 663,716 shares of the stock in a transaction dated Tuesday, August 21st. The shares were acquired at an average cost of $2.26 per share, for a total transaction of $1,499,998.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.40% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning acquired a new stake in shares of AVEO Pharmaceuticals during the second quarter worth $143,000. Rhumbline Advisers acquired a new stake in shares of AVEO Pharmaceuticals during the second quarter worth $209,000. Birchview Capital LP lifted its holdings in shares of AVEO Pharmaceuticals by 20.0% during the third quarter. Birchview Capital LP now owns 120,000 shares of the biopharmaceutical company’s stock worth $397,000 after purchasing an additional 20,000 shares during the period. Granahan Investment Management Inc. MA lifted its holdings in shares of AVEO Pharmaceuticals by 16.3% during the second quarter. Granahan Investment Management Inc. MA now owns 179,512 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 25,134 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of AVEO Pharmaceuticals by 661.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 218,129 shares of the biopharmaceutical company’s stock worth $493,000 after purchasing an additional 189,500 shares during the period. 50.84% of the stock is owned by hedge funds and other institutional investors.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: How to Use a Moving Average for Trading 

The Fly

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.